Skip Ribbon Commands
Skip to main content
 


Lung Cancer Mutation Consortium Protocol


Trial Focus

Lung Cancer

Objective

         Patients with stage IIIB / IV adenocarcinoma of the lung who have undergone biopsy with remnant tissue. All patients will have adequate remnant tissues to have their tumors tested for mutations. The study sample size will be 1000. Patients who were origin

IRB Protocol #

09-0756

Trial Status

OPEN

Principle Investigator

PAUL BUNN

Sponsor

NCI

Contact

KELLY KUGLER at (303)724-4168 or KELLY.KUGLER@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : Patients will be asked to donate samples from a biopsy (a tissue sample from the tumor) or surgery that has already occurred. They will be asked to fill out a short questionnaire. It will ask them about their cancer history and treatments, current medications, smoking history, toxic exposure history and family history of cancer. // Eligibility criteria : 1.Subjects (=> 18 years of age) who are undergoing further evaluation for the diagnosis or treatment of advanced adenocarcinoma of the lung. 2.Oral and written informed consent. 3.Participants must have a SWOG performance status of 0-2. Eligibility criteria : 1.Subjects (=> 18 years of age) who are undergoing further evaluation for the diagnosis or treatment of advanced adenocarcinoma of the lung. 2.Oral and written informed consent. 3.Participants must have a SWOG performance status of 0-2.